Scarica l'app Stockscreener
26.54
0.97%
-0.26
Precedente Chiudi:
$26.80
Aprire:
$26.77
Volume 24 ore:
1.24M
Relative Volume:
0.44
Capitalizzazione di mercato:
$3.31B
Reddito:
$22.12M
Utile/perdita netta:
$-245.15M
Rapporto P/E:
-6.8853
EPS:
-3.8546
Flusso di cassa netto:
$-373.40M
1 W Prestazione:
+1.34%
1M Prestazione:
+20.04%
6M Prestazione:
+500.45%
1 anno Prestazione:
+420.39%
Intervallo 1D:
$26.00
$28.00
Intervallo di 1 settimana:
$24.80
$28.00
Portata 52W:
$2.7601
$28.29
Alumis Inc Stock (ALMS) Company Profile
Nome
Alumis Inc
Settore
Industria
Telefono
650-231-6625
Indirizzo
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
26.54 | 3.34B | 22.12M | -245.15M | -373.40M | -3.8546 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-21 | Iniziato | Chardan Capital Markets | Buy |
| 2025-07-25 | Iniziato | Wells Fargo | Overweight |
| 2025-06-10 | Ripresa | Guggenheim | Buy |
| 2025-01-30 | Iniziato | Oppenheimer | Outperform |
| 2024-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Iniziato | Guggenheim | Buy |
| 2024-07-23 | Iniziato | Leerink Partners | Outperform |
| 2024-07-23 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Alumis Inc Borsa (ALMS) Ultime notizie
Aug Opening: Is Alumis Inc gaining market shareTrade Ideas & Community Shared Stock Ideas - baoquankhu1.vn
Can Alumis Inc. expand into new markets2025 Momentum Check & Short-Term Swing Trade Alerts - mfd.ru
Alumis (NASDAQ:ALMS) Shares Up 7.2%Still a Buy? - MarketBeat
Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit - Yahoo Finance
Is Alumis Inc.’s growth already priced inPortfolio Growth Summary & Weekly Watchlist of Top Performers - mfd.ru
Quarterly Risk: Is Alumis Inc in a consolidation phase2025 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - AOL.com
Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price Momentum - Yahoo Finance
EPS Watch: Can Alumis Inc ride the EV waveWeekly Stock Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Market Leaders: Will TWFG outperform the market in YEARTrade Analysis Report & High Win Rate Trade Alerts - baoquankhu1.vn
Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook - Sahm
Alumis to Participate in Upcoming February Investor Conferences - The Manila Times
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Alumis and ACELYRIN announce merger in all-stock deal - MSN
Alumis (NASDAQ:ALMS) Stock Price Up 9.8%What's Next? - MarketBeat
Alumis Inc stock (ALMS) jumps again on Nasdaq — here’s what’s driving the move and what comes next - TechStock²
Why Alumis Inc. Stock Is Suddenly Powering Higher - TipRanks
Chardan highlights Alumis’s (ALMS) potential after envudeucitinib hits all phase 3 endpoints in psoriasis trials - MSN
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Top Small Cap Stocks To Watch NowJanuary 6th - MarketBeat
Chardan Highlights Alumis's (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Finviz
Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Insider Monkey
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January - MarketBeat
Alumis stock hits all-time high at 27.28 USD By Investing.com - Investing.com Australia
Alumis Inc. (ALMS) Stock Analysis: A Biotech Contender With A 34.43% Potential Upside - DirectorsTalk Interviews
10 New Stocks on the Rise - Insider Monkey
Alumis (NASDAQ:ALMS) Hits New 12-Month HighStill a Buy? - MarketBeat
Alumis stock hits all-time high at 27.28 USD - Investing.com
Alumis (NASDAQ:ALMS) Trading Up 6.4%Should You Buy? - MarketBeat
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - AOL.com
Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Chardan Capital - MarketBeat
Alumis stock reaches all-time high at 25.25 USD By Investing.com - Investing.com Australia
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Chardan Capital initiates coverage on Alumis stock with Buy rating - Investing.com
Chardan Capital initiates coverage on Alumis stock with Buy rating By Investing.com - Investing.com Nigeria
Profit Recap: Is now the right time to enter ASTCJuly 2025 WrapUp & Technical Confirmation Alerts - baoquankhu1.vn
Trading Recap: Is Alumis Inc gaining market shareJuly 2025 Market Mood & Growth Focused Entry Point Reports - baoquankhu1.vn
Aug Reactions: What is the long term forecast for XPLR Infrastructure LP Limited Partnership stock - baoquankhu1.vn
Alumis stock reaches all-time high at 25.25 USD - Investing.com
Aug Weekly: What’s Enterprise Products Partners L.P. Limited Partnership’s historical returnMarket Activity Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - 24/7 Wall St.
Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity Raise - Yahoo Finance
Alumis Inc Azioni (ALMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):